ライフサイエンスコーパス: ambulatory patient

1 WiFi-enabled iPod to obtain ECGs (iECGs) in ambulatory patients.

2 trials and in reducing ischemic episodes in ambulatory patients.

3 ucose meter system in critical care/hospital/ambulatory patients.

4 reatment of early neurologic Lyme disease in ambulatory patients.

5 on medical outcomes other than mortality in ambulatory patients.

6 cycline for early neurologic Lyme disease in ambulatory patients.

7 o 15 years, improved the conditions of the 3 ambulatory patients.

8 DESIGN Family study of ambulatory patients.

9 ated with higher cardiovascular mortality in ambulatory patients.

10 r pharmacological stress echo in a cohort of ambulatory patients.

11 n this nationwide sample of hospitalized and ambulatory patients.

12 undergoing minor surgical procedures and 562 ambulatory patients.

13 ry 30 minutes of time spent scheduled to see ambulatory patients.

14 limited and not relevant to the majority of ambulatory patients.

15 , has been successful in normal subjects and ambulatory patients.

16 xis may be appropriate for some HIV-infected ambulatory patients.

17 alized patients, (2) 0.80 for noncholestatic ambulatory patients, (3) 0.87 for PBC patients, and (4)

18 Of 10 ambulatory patients, 5 died from untreated VF, 4 had car

19 Of 6441 ambulatory patients (79 percent of all ED visits) who we

20 A total of 3045 patents (49 percent of ambulatory patients and 37 percent of total ED visits) w

21 5 patients with HIV/AIDS from two sites: 148 ambulatory patients and 47 patients who had been recentl

22 r improving pancreatic tail visualization in ambulatory patients and is superior to the use of water

23 nous nutritional support of hospitalized and ambulatory patients, and that pharmaceutical manufacture

24 Although many ambulatory patients appear to have nonurgent conditions

25 er, overall patterns of antibiotic use among ambulatory patients are not well understood.

26 Telehealth can be safely used in selected ambulatory patients as a substitute for the standard pos

27 h severe limitation was less common than for ambulatory patients enrolled in INTERMACS before ventric

28 Thus, records of 456 ambulatory patients evaluated for Cbl deficiency at a st

29 In ambulatory patients evaluated for obstructive coronary d

30 The role exercise testing plays in selecting ambulatory patients for heart transplantation is emphasi

31 ngle-lead iECG with remote interpretation in ambulatory patients >/=65 years of age at increased risk

32 in the case group were well-functioning and ambulatory patients having COPD as determined by their h

33 ging from 5.1% for the 2097 hospitalized and ambulatory patients (in six study cohorts) to 36.5% for

34 Long-term statin administration in ambulatory patients is associated with a reduced risk of

35 Antibiotic use in ambulatory patients is decreasing in the United States.

36 lements of primary care in their approach to ambulatory patients is unknown.

37 laide, Australia, among overweight and obese ambulatory patients (N = 150) with symptomatic atrial fi

38 (Se)/specificities (Sp) for diagnosis in an ambulatory patient of obstructive coronary disease (> or

39 clusion: Primary care physicians with busier ambulatory patient practices delivered lower-quality dia

40 Primary care physicians with busier ambulatory patient practices delivered lower-quality dia

41 Consecutive ambulatory patients presenting for care.

42 We retrospectively studied 181 ambulatory patients referred to the Saint Louis Universi

43 Ambulatory patients reported varied experiences after DT

44 ontinued medications represents an important ambulatory patient safety concern.

45 Most ambulatory patients seek care in an ED because of worris

46 Single measurements in 27 ambulatory patients showed elevated CK (953 U/l; 562 to

47 study, we analyzed data on hospitalized and ambulatory patients spanning 22 years (1985-2006) and 10

48 In the ambulatory patient, the main goal is to maximize functio

49 ed from February 1 to August 31, 2015, among ambulatory patients undergoing breast reconstruction at

50 n order to direct antiemetic prophylaxis for ambulatory patients undergoing office-based anesthesia.

51 Participants were ambulatory patients who received a prescription from a d

52 The study population consisted of 1552 ambulatory patients who underwent pharmacological (752 d

53 acute infectious syndromes to management of ambulatory patients with acute or chronic infections; ho

54 data on 80 clinical characteristics from 268 ambulatory patients with advanced heart failure (derivat

55 INTERMACS profiles help identify ambulatory patients with advanced HF who may benefit fro

56 palliative and oncology care is feasible in ambulatory patients with advanced NSCLC.

57 Ambulatory patients with advanced urothelial carcinoma w

58 vular atrial fibrillation, but its use among ambulatory patients with atrial fibrillation has not bee

59 In a large, contemporary cohort of ambulatory patients with atrial fibrillation who receive

60 Prophylaxis is not currently recommended for ambulatory patients with cancer (with exceptions) or for

61 diagnose narcolepsy might be most useful in ambulatory patients with cataplexy but with a normal mul

62 used to further prognostically risk stratify ambulatory patients with CHF referred for heart transpla

63 independently predicts adverse prognosis in ambulatory patients with CHF.

64 be used as a disease-specific instrument in ambulatory patients with cholestatic liver disease.

65 ted at any time during clinical follow-up in ambulatory patients with chronic heart failure are highl

66 imal treadmill exercise were measured in 185 ambulatory patients with chronic heart failure who had b

67 provide important prognostic information in ambulatory patients with chronic heart failure with syst

68 ristics and long-term prognosis of anemia in ambulatory patients with chronic heart failure.

69 In ambulatory patients with chronic mild to moderate diasto

70 A total of 126 ambulatory patients with chronic renal failure treated w

71 f cardiac troponin I (cTnI) in asymptomatic, ambulatory patients with chronic renal failure treated w

72 We followed up 558 consecutive ambulatory patients with chronic, stable systolic HF (le

73 Nineteen ambulatory patients with clinically active disease were

74 (CrCl) in relation to 6-min walk distance in ambulatory patients with congestive heart failure (HF).

75 prognostic accuracy of identifying high risk ambulatory patients with congestive heart failure consid

76 In ambulatory patients with congestive HF, estimated CrCl p

77 Among ambulatory patients with coronary artery disease or CHF,

78 thiazolidinedione (TZD) use and outcomes in ambulatory patients with diabetes and heart failure (HF)

79 marker concentrations were ascertained in 86 ambulatory patients with established heart failure.

80 In ambulatory patients with established HF and diabetes, th

81 ICG) in predicting clinical deterioration in ambulatory patients with heart failure (HF).

82 e of risk prediction models for mortality in ambulatory patients with heart failure and describe thei

83 Ambulatory patients with heart failure tended to substan

84 stimate more than 50% 1-year mortality among ambulatory patients with heart failure who die in the su

85 nformation that can be used to risk stratify ambulatory patients with heart failure with ischemic or

86 death declined substantially over time among ambulatory patients with heart failure with reduced ejec

87 luable independent prognostic information in ambulatory patients with heart failure.

88 ssess heart transplantation (HTx) urgency in ambulatory patients with heart failure.

89 stem provides additional risk information in ambulatory patients with heart failure.

90 ed with outcomes in a well-treated cohort of ambulatory patients with HF although it did not signific

91 d long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failur

92 modified sandwich immunoassay in consecutive ambulatory patients with HF who were followed up for 4.1

93 etected during routine clinical follow-up of ambulatory patients with HF, are highly associated with

94 s have dramatically improved the survival of ambulatory patients with HF, outcomes for patients with

95 e as an initial prognostic screening tool in ambulatory patients with impaired systolic function who

96 Despite proven benefit in ambulatory patients with ischemic heart disease, the pat

97 mmune suppressive therapy and HSC support in ambulatory patients with less accumulated disability and

98 patients with HD screened for the study, 37 ambulatory patients with manifest HD (mean [SD] age, 52.

99 f of headache in approximately 55 percent of ambulatory patients with migraine.

100 nt consensus guidelines for the treatment of ambulatory patients with mild to severe active UC.

101 Forty-five ambulatory patients with MS (34 women, 11 men) and 25 se

102 High-risk ambulatory patients with New York Heart Association clas

103 ilure, to assess the mode of death in 10,538 ambulatory patients with New York Heart Association clas

104 reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease.

105 Ambulatory patients with no visceral metastases and more

106 referred to as "hospitalized" patients), (2) ambulatory patients with noncholestatic cirrhosis, (3) p

107 Ambulatory patients with NSCLC, aged 75 years or younger

108 rocardiographic databases to identify 13 559 ambulatory patients with NVAF from July 1996 through Dec

109 urological disease (1.0+/-0.9) controls, and ambulatory patients with Parkinson's disease (1.8+/-1.1)

110 A total of 75 consecutive ambulatory patients with persistent advanced heart failu

111 The need for heart transplantation in ambulatory patients with severe heart failure is better

112 ve advanced malignant conditions, and 90% of ambulatory patients with spinal cord compression can rem

113 We prospectively studied 15 ambulatory patients with stable coronary disease who wer

114 iation exposure and cost of care in low-risk ambulatory patients with symptoms of acute coronary synd

115 Ambulatory patients with systolic HF, a heavy symptom bu

116 nd newly diagnosed tuberculosis (hereafter, "ambulatory patients with tuberculosis"), and 58 ambulato

117 mong hospitalized patients, 19.1 ng/mL among ambulatory patients with tuberculosis, and 5.9 ng/mL amo

118 ients with tuberculosis, and 5.9 ng/mL among ambulatory patients without tuberculosis (P < .001).

119 ection and without tuberculosis (hereafter, "ambulatory patients without tuberculosis").